V1 and others on the thread wanted to call HIV and OSTE to your attention. Both have had considerable runs. Below is a release from HIV. In addition the have just successfully vaccineated mice against herpes simplex. OSTE was recommended by a friend (non-bio) who has made some incredible moonshots this year. Just wanted to call these two to the thread's attention.
>>Monday October 6 8:30 AM EDT
Company Press Release
CEL-SCI Corporation Announces Clinical Trial Results In Head and Neck Cancer Patients
ALEXANDRIA, Va., Oct. 6 /PRNewswire/ -- CEL-SCI Corporation (Amex:HIV) today announced that Dr. Raphael Feinmesser of the Rabin Medical Center, Tel Aviv University, Israel, presented initial results at the First Annual Congress on Leukocyte Interleukin Injection (Multikine(TM)), held in Alexandria, Virginia, from an ongoing clinical study with Multikine in head and neck cancer patients. He reported that his first four patients have all had substantial tumor reductions in a period of only 3 weeks, at which point the clinical protocol required him to conduct surgery or radiation, the normal treatments of choice. This result was achieved with no side effects. Observations made by various presenters using Multikine in head and neck cancer trials include the reduction or elimination of pain from the tumor. In addition, some patients noted that their ability to talk, chew and swallow, which had been compromised by the tumor, was improved.
Dr. Feinmesser's study, when finished, will involve 10 patients divided into 2 dosage groups. The protocol calls for the treatment of newly diagnosed patients with Multikine before using surgery or radiation, the normal treatments of choice. Multikine therapy is given during the first two weeks, with surgery or radiation to follow after week 3. A similar clinical trial involving 14 patients being treated with Multikine was started in Montreal, Canada last month. CEL-SCI hopes to complete these two studies by the second quarter of 1998.
Multikine is a natural mixture of human immune system regulators called cytokines. It contains Interleukin-2 and other cytokines, several of which are being investigated individually as potential cancer treatments. Multikine is also in clinical trials in the U.S. and Canada for head and neck cancer patients who have failed at least one treatment therapy. In addition, it is being tested in HIV-1 infected patients to determine its safety and look for evidence of effects on immune cell functions and viral load.
Head and neck cancer is the sixth most frequently occurring cancer worldwide, with an incidence of 500,000 annually. Recent statistics show no reduction in head and neck cancer mortality, but rather a dramatic increase of the disease in certain segments of the population. This cancer is most frequently found in men in their 50's or early 60's with a history of smoking and alcohol consumption. Conventional treatment calls for either surgery, which can be extremely disfiguring, or radiation and chemotherapy, both of which are associated with very unpleasant side-effects.
CEL-SCI Corporation is a pioneer in the field of natural immunotherapy. The Company is developing immune based treatments for cancer, AIDS, tuberculosis, malaria and herpes simplex.
''CEL-SCI press releases are available through Company News On-Call by fax, 800-758-5804, Ext. 445563, or at prnewswire.com on the Internet.''
When used in this report, the words ''intend,'' ''believes,'' ''anticipated'' and ''expects'' and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1996. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. << |
